Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2015

View Archived Issues

Regeneron designs human antibodies to PD-1

New MoA: Novel ATAD2 bromodomain inhibitors

Thomas Jefferson University and University of Pennsylvania present fusion proteins

FDA grants orphan drug designation to MTG-201 for mesothelioma

Medivation to acquire all worldwide rights to talazoparib from BioMarin

IDMC recommends reduction of cardiac toxicity monitoring in PRESENT trial

FDA accepts IND application for tazemetostat in INI1-negative tumors or synovial sarcoma

RetroSense Therapeutics' RST-001 obtains FDA clearance to proceed to first-in-human trials

Jacobus Pharmaceutical reports development of novel antimalarials

Unsolicited offer to acquire InSite Vision deemed as better than QLT's proposal

Clinical trial results detailed for tofacitinib in psoriasis

Daiichi Sankyo announces Japanese approvals for supplementary indications

Esperance and MD Anderson Cancer Center form EP-100 alliance

Researchers confirm brain-selectivity of estrogen prodrug, potential for menopause disorders

FDA awards breakthrough therapy designation to cabozantinib for RCC

FDA approves Promacta for young children with chronic ITP

Remicade approved in Japan for entero-Behcet's, neuro-Behcet's and vasculo-Behcet's disease

Roche acquires nucleic acid purification assets from Lumora

TxCell receives French government grant to fund Col-Treg development

Filings accepted for afatinib as second-line treatment for squamous cell carcinoma of the lung

Pfizer conducting first-in-human study of PF-06751979

Cristal Therapeutics initiates phase I study of CriPec docetaxel for solid tumors

Lundbeck announces progress of second quarter 2015 and restructuring

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...